NM_032735.3(BEST3):c.254A>C (p.Tyr85Ser) AND not specified
- Germline classification:
- Uncertain significance (1 submission)
- Last evaluated:
- Aug 9, 2021
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV004093727.1
Allele description [Variation Report for NM_032735.3(BEST3):c.254A>C (p.Tyr85Ser)]
NM_032735.3(BEST3):c.254A>C (p.Tyr85Ser)
Condition(s)
- Synonyms:
- AllHighlyPenetrant
- Identifiers:
- MedGen: CN169374
-
cytochrome oxidase subunit 3, partial (mitochondrion) [Porites lobata]
cytochrome oxidase subunit 3, partial (mitochondrion) [Porites lobata]gi|2706096169|gb|WYD57432.1|Protein
-
Biston falcata isolate 20379 cytochrome c oxidase subunit I (COI) gene, partial ...
Biston falcata isolate 20379 cytochrome c oxidase subunit I (COI) gene, partial cds; mitochondrialgi|1561854622|gb|MK068857.1|Nucleotide
-
CBST1737.rev NICHD_XGC_tropThy1 Xenopus tropicalis cDNA clone IMAGE:8923854 3', ...
CBST1737.rev NICHD_XGC_tropThy1 Xenopus tropicalis cDNA clone IMAGE:8923854 3', mRNA sequencegi|126549684|gnl|dbEST|45063558|gb| 199.1|Nucleotide
-
Table of included studies and associated publications - Erlotinib and gefitinib ...
Table of included studies and associated publications - Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Oct 26, 2024